Breaking News Instant updates and real-time market news.

LMAT

LeMaitre

$31.29

-0.03 (-0.10%)

19:37
10/13/19
10/13
19:37
10/13/19
19:37

LeMaitre acquires biologic patch business from Admedus

LeMaitre Vascular announced that it has acquired the biologic patch business of Admedus for $15.5M, of which $14.2M was paid at closing and $1.3M is due in two post-closing installments, as well as potential earnout payments of $7.8M payable based upon performance of the acquired business as well as other milestones. The parties also signed a license agreement for the tissue processing technology limited to the CardioCel and VascuCel product lines and a transition services agreement under which Admedus will continue to manufacture the products for up to three years while LeMaitre Vascular transitions manufacturing to its U.S. headquarters. LeMaitre Vascular will not take ownership of the Admedus factory in Perth, Australia. The acquired patches, marketed under the brands CardioCel and VascuCel, are processed in a manner that is intended to reduce the risk of calcification. Annualized 2019 sales of these product lines were $7.1M, mostly in the U.S. and Europe.

  • 23

    Oct

LMAT LeMaitre
$31.29

-0.03 (-0.10%)

02/20/19
LSCM
02/20/19
NO CHANGE
Target $27
LSCM
Hold
LeMaitre price target raised to $27 from $24 at Lake Street
Lake Street analyst Brooks O'Neil raised his price target for LeMaitre Vascular to $27 saying the company reported "solid" Q4 results as RestoreFlow and Valvulotomes recovered from Q3. However, management does not appear ready to suggest 10% sales and 20% earnings growth "are again in focus," O'Neil tells investors in a post-earnings research note. He keeps a Hold rating on LeMaitre.
07/25/19
FANA
07/25/19
UPGRADE
Target $37
FANA
Outperform
LeMaitre upgraded to Outperform from Neutral at First Analysis
First Analysis analyst Joseph Munda upgraded LeMaitre to Outperform from Neutral and raised his price target for the shares to $37 from $29. The analyst sees strengthening fundamentals following the company's Q2 results. Management's renewed sense of confidence in the business, coupled with a raised outlook for 2019-2020, warrants an upgrade to Outperform, Munda tells investors in a research note.
07/25/19
BRRR
07/25/19
NO CHANGE
Target $37
BRRR
Outperform
LeMaitre price target raised to $37 from $32 at Barrington
Barrington analyst Michael Petusky raised his price target for LeMaitre Vascular to $37 from $32 following the company's "solid" Q2 results. The analyst is "encouraged" by recent sales trends and thinks the company's margins could expand "meaningfully" over the next couple of years. The recent geographic expansion and new product innovations, like the just-launched XenoSure Plus, will give LeMaitre a "reasonable opportunity" to sustain its recent pickup in organic momentum over the longer term, Petusky tells investors in a research note. He maintains an Outperform rating on the shares.
07/25/19
LSCM
07/25/19
NO CHANGE
Target $34
LSCM
Hold
LeMaitre price target raised to $34 from $27 at Lake Street
Lake Street analyst Brooks O'Neil raised his price target for LeMaitre Vascular to $34 from $27 saying the company reported solid" Q2 results. The analyst, however, is hesitant to value the company at a premium to its peer group. He views the stock as fairly valued at current levels and keeps a Hold rating on the name.

TODAY'S FREE FLY STORIES

GOLD

Barrick Gold

$16.57

-0.095 (-0.57%)

15:40
11/17/19
11/17
15:40
11/17/19
15:40
Periodicals
Saracen close to buying Barrick Gold mine stake for $750M, Bloomberg says »

Saracen Mineral Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESPR

Esperion

$40.51

0.67 (1.68%)

15:11
11/17/19
11/17
15:11
11/17/19
15:11
Hot Stocks
Esperion presents pooled analyses from four Phase 3 bempedoic acid studies »

Esperion announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 26

    Feb

PCG

PG&E

$7.41

0.71 (10.60%)

15:06
11/17/19
11/17
15:06
11/17/19
15:06
Hot Stocks
PG&E monitoring potential weather event that could lead to power shutoffs »

Pacific Gas and Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

XRX

Xerox

$38.95

0.295 (0.76%)

, HPQ

HP Inc.

$20.17

0.05 (0.25%)

15:04
11/17/19
11/17
15:04
11/17/19
15:04
Hot Stocks
HP unanimously rejects unsolicited Xerox proposal »

HP Inc. (HPQ) announced…

XRX

Xerox

$38.95

0.295 (0.76%)

HPQ

HP Inc.

$20.17

0.05 (0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 09

    Dec

FOX

Fox Corp.

$33.60

0.14 (0.42%)

, FOXA

Fox Corp.

$34.26

0.04 (0.12%)

14:49
11/17/19
11/17
14:49
11/17/19
14:49
On The Fly
Box Office Battle: 'Ford v Ferrari' races to top, 'Charlie's Angels' disappoints »

"Box Office Battle" is…

FOX

Fox Corp.

$33.60

0.14 (0.42%)

FOXA

Fox Corp.

$34.26

0.04 (0.12%)

LGF.A

Lionsgate

$9.67

0.315 (3.37%)

LGF.B

Lionsgate

$9.07

0.345 (3.96%)

SNE

Sony

$62.03

0.23 (0.37%)

VIA

Viacom

$26.59

1.28 (5.06%)

VIAB

Viacom

$23.07

0.59 (2.62%)

T.CA

TELUS Corp. (Toronto)

$0.00

(0.00%)

CMCSA

Comcast

$44.54

-0.93 (-2.05%)

CMCSK

Comcast

$0.00

(0.00%)

DIS

Disney

$144.63

-2.56 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

JNJ

Johnson & Johnson

$134.97

3.99 (3.05%)

13:36
11/17/19
11/17
13:36
11/17/19
13:36
Periodicals
J&J rushed to test baby powder and got complicated results, WSJ says »

In October, Johnson &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 07

    Dec

  • 21

    Jan

BA

Boeing

$371.55

4.25 (1.16%)

13:24
11/17/19
11/17
13:24
11/17/19
13:24
Periodicals
Boeing 737 makes emergency landing after engine malfunction, NY Post says »

A Canada-bound flight…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$47.46

0.09 (0.19%)

13:17
11/17/19
11/17
13:17
11/17/19
13:17
Hot Stocks
Data shows AstraZeneca's Brilinta reduces risks of clinically relevant bleeding »

New results from a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 07

    Dec

LLY

Eli Lilly

$113.18

1.8 (1.62%)

13:11
11/17/19
11/17
13:11
11/17/19
13:11
Hot Stocks
Analysis shows Jardiance decreased risk of hospitalization for heart failure »

A new interim analysis of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

AZN

AstraZeneca

$47.46

0.09 (0.19%)

13:09
11/17/19
11/17
13:09
11/17/19
13:09
Hot Stocks
AstraZeneca says data shows Farxiga reduces risks in heart failure patients »

AstraZeneca announced new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 07

    Dec

BA

Boeing

$371.55

4.25 (1.16%)

13:05
11/17/19
11/17
13:05
11/17/19
13:05
Hot Stocks
Boeing, Biman announce order for two 787-9 Dreamliner jets »

Boeing and Biman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBIO

BridgeBio

$28.26

0.55 (1.98%)

, EIDX

Eidos Therapeutics

$46.58

1.33 (2.94%)

13:03
11/17/19
11/17
13:03
11/17/19
13:03
Hot Stocks
BridgeBio, Eidos present 'positive' data from Phase 2 clinical trial of AG10 »

BridgeBio Pharma (BBIO)…

BBIO

BridgeBio

$28.26

0.55 (1.98%)

EIDX

Eidos Therapeutics

$46.58

1.33 (2.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 21

    Nov

CLBS

Caladrius

$2.64

-0.06 (-2.22%)

13:01
11/17/19
11/17
13:01
11/17/19
13:01
Hot Stocks
Caladrius reports 'positive' results for CLBS16 from ESCaPE-CMD trial »

Caladrius Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KNSA

Kiniksa

$6.52

0.1 (1.56%)

12:59
11/17/19
11/17
12:59
11/17/19
12:59
Hot Stocks
Kiniksa presents Rilonacept final Phase 2 clinical data »

Kiniksa Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 21

    Nov

MDCO

The Medicines Co.

$51.92

1.03 (2.02%)

12:57
11/17/19
11/17
12:57
11/17/19
12:57
Hot Stocks
The Medicines Co's ORION-10 study of Inclisiran met primary, secondary endpoints »

The Medicines Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$220.84

2.29 (1.05%)

12:54
11/17/19
11/17
12:54
11/17/19
12:54
Hot Stocks
Amgen analysis shows benefit of Repatha in high risk patients »

Amgen announced a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

CNI

Canadian National

$93.64

0.46 (0.49%)

12:52
11/17/19
11/17
12:52
11/17/19
12:52
Hot Stocks
Canadian National receives strike notice from train conductor union »

CN said that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 22

    Nov

ADAP

Adaptimmune

$0.71

-0.0959 (-11.87%)

12:51
11/17/19
11/17
12:51
11/17/19
12:51
Hot Stocks
Adaptimmune data confirms ADP-A2M4 delivers clinical benefit »

Adaptimmune Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CELG

Celgene

$110.02

-0.01 (-0.01%)

, BMY

Bristol-Myers

$58.61

0.11 (0.19%)

12:47
11/17/19
11/17
12:47
11/17/19
12:47
Hot Stocks
Bristol-Myers sees no further extension for Celgene notes due to merger closing »

Bristol-Myers Squibb…

CELG

Celgene

$110.02

-0.01 (-0.01%)

BMY

Bristol-Myers

$58.61

0.11 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 04

    Dec

  • 07

    Dec

  • 25

    Mar

  • 04

    Apr

ETNB

89bio

$26.03

3.03 (13.17%)

, YAYO

YayYo

$3.65

-0.29 (-7.36%)

11:09
11/17/19
11/17
11:09
11/17/19
11:09
On The Fly
Opening Day: 89bio has strong opening week »

89bio (ETNB) finished its…

ETNB

89bio

$26.03

3.03 (13.17%)

YAYO

YayYo

$3.65

-0.29 (-7.36%)

CAN

Canaan

$0.00

(0.00%)

SITM

SiTime

$0.00

(0.00%)

BABA

Alibaba

$185.44

2.75 (1.51%)

YXR

YX Asset Recovery

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 22

    Nov

WFC

Wells Fargo

$53.80

0.3 (0.56%)

, AAPL

Apple

$265.73

3.07 (1.17%)

10:01
11/16/19
11/16
10:01
11/16/19
10:01
Periodicals
Berkshire Hathaway inactive with record cash hoard, Barron's says »

Berkshire Hathaway…

WFC

Wells Fargo

$53.80

0.3 (0.56%)

AAPL

Apple

$265.73

3.07 (1.17%)

OXY

Occidental Petroleum

$38.94

1.18 (3.13%)

BRK.B

Berkshire Hathaway

$219.74

0.38 (0.17%)

BRK.A

Berkshire Hathaway

$329,361.11

266.11 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jan

DIS

Disney

$144.63

-2.56 (-1.74%)

09:43
11/16/19
11/16
09:43
11/16/19
09:43
Periodicals
Disney+ may not be able to hold onto huge number of subs, Barron's says »

While Disney's (DIS)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$112.11

2.9 (2.66%)

09:27
11/16/19
11/16
09:27
11/16/19
09:27
Periodicals
Medtronic shares 'could rise even more,' Barron's says »

Barron's recommended…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

BR

Broadridge

$119.80

0.485 (0.41%)

09:18
11/16/19
11/16
09:18
11/16/19
09:18
Periodicals
Broadridge a defensive name that can withstand slowdown, Barron's says »

Broadridge Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCD

McDonald's

$193.95

-0.02 (-0.01%)

, MDT

Medtronic

$112.11

2.9 (2.66%)

09:07
11/16/19
11/16
09:07
11/16/19
09:07
Periodicals
Barron's suggests dividend stocks for retirement savers »

In this week's…

MCD

McDonald's

$193.95

-0.02 (-0.01%)

MDT

Medtronic

$112.11

2.9 (2.66%)

KO

Coca-Cola

$52.67

0.03 (0.06%)

PRU

Prudential

$93.61

0.82 (0.88%)

SYF

Synchrony

$37.05

0.34 (0.93%)

KEY

KeyCorp

$18.96

0.1 (0.53%)

T

AT&T

$39.49

0.53 (1.36%)

AMGN

Amgen

$220.84

2.29 (1.05%)

CSCO

Cisco

$45.10

0.18 (0.40%)

RCL

Royal Caribbean

$117.91

2.69 (2.33%)

MRK

Merck

$84.89

0.33 (0.39%)

JNJ

Johnson & Johnson

$134.97

3.99 (3.05%)

MSFT

Microsoft

$149.95

1.89 (1.28%)

JPM

JPMorgan

$129.51

0.83 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 18

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 22

    Nov

  • 02

    Dec

  • 04

    Dec

  • 07

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 14

    Jan

  • 21

    Jan

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 29

    Jan

  • 05

    Feb

  • 12

    Feb

  • 14

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.